Cargando…

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume

To improve the detection of prostate cancer (PCa) by combining the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) and prostate-specific antigen–age volume (PSA–AV), especially among those in gray zone with PI-RADS v2 score 3 or serum total prostate-specific antigen (tPSA) 4 to 10 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yuan-Fei, Zhang, Qian, Chen, Hai-Yan, Chen, Jie-Yu, Pan, Yao, Xu, Cong-Cong, Xu, Jian-Xia, Yu, Ri-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616591/ https://www.ncbi.nlm.nih.gov/pubmed/31261602 http://dx.doi.org/10.1097/MD.0000000000016289

Ejemplares similares

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
por: Zhang, Cong, et al.
Publicado: (2021)

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
por: Chen, Ming, et al.
Publicado: (2021)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone
por: Liu, Junxiao, et al.
Publicado: (2020)

MXene-assisted organic electrochemical transistor biosensor with multiple spiral interdigitated electrodes for sensitive quantification of fPSA/tPSA
por: Zhu, Yi-Cheng, et al.
Publicado: (2021)

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone
por: Wen, Jing, et al.
Publicado: (2022)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer
por: Qian, Yu-Hang, et al.
Publicado: (2023)

Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone
por: Guo, Zhui-Feng, et al.
Publicado: (2021)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone
por: Liu, Fei, et al.
Publicado: (2022)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report
por: Jia, Hanna, et al.
Publicado: (2022)

Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA
por: Mello-Grand, Maurizia, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

The Impact of Prostate Volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a Real-World Setting
por: Volz, Yannic, et al.
Publicado: (2023)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer
por: Zheng, Song, et al.
Publicado: (2019)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Do prostate-specific antigen parameters have a similar role in predicting prostate cancer regardless of serum testosterone levels in men with gray-zone prostate-specific antigen levels?
por: Oh, Jeong Hoon, et al.
Publicado: (2022)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

A Comparative Study: Has MRI-guided Fusion Prostate Biopsy Changed the Prostate-specific Antigen Gray-zone Range?
por: Sönmez, Gökhan, et al.
Publicado: (2019)

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies
por: Zhang, Li, et al.
Publicado: (2022)

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions
por: Hu, Can, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jg1fv5erfi77kan1jfjcjtju67